Standard
Phase 3Small molecule
Standard is one of 72 small molecule programs targeting Liver Transplant. It is currently in Phase 3.
3
Indications
6
Total Trials
2
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
353 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1Standard
UUniversity of Virginia
Phase 3
Vemlidy
GileadPreclinical
Octreotide
Johnson & JohnsonPreclinical
Lenvima
EisaiPreclinical
Myfortic
NovartisPreclinical
Myfortic
NovartisPreclinical
Cyklokapron
AAmring
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
IC-Green
CCHX Technologies Inc.
Preclinical
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Transplant1 trial
Sedation1 trial
Core Temperature Variations During Midazolam vs Propofol Sedation for Neuraxial Anesthesia
Completed·—·N/A·NCT02502877·27 enrolled
Tranexamic Acid1 trial
Tranexamic Acid During Colonic Endoscopic Resection Procedures
Recruiting·—·Phase 4·NCT05345613·200 enrolled
1 more indication
Lidocaine1 trial
Efficacy of Lidocaine Gel in Reducing Foley Catheter Discomfort in Surgical Patients
Unknown status·—·Phase 4·NCT02709304·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Standard. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Virginia